Sign inCreate account

Report workspace tools

NCT06123754RECRUITINGanonymous

A Randomized, Controlled, Double-blind, Multicenter Phase III Clinical Study of Envafolimab Plus Platinum-based Doublet Chemotherapy Versus Placebo Plus Platinum-based Doublet Chemotherapy in Patients With Non-small Cell Lung Cancer

Sponsor

Source record

3D Medicines (Sichuan) Co., Ltd.

Phase

Source record

PHASE3

Modality

AI-normalized

monoclonal antibody

Target

AI-normalized

Envalfolimab subcutaneously injected+Platinum-based doublet chemotherapy intravenous injection, placebo subcutaneously injected +Platinum-based doublet chemotherapy intravenous injection

Indication / condition

AI-normalized

Non-small Cell Lung Cancer

Intervention

Source record

Envalfolimab subcutaneously injected+Platinum-based doublet chemotherapy intravenous injection, placebo subcutaneously injected +Platinum-based doublet chemotherapy intravenous injection

Source & freshness

Source record

NCT ID

NCT06123754

Original source

ClinicalTrials.gov

Source last updated

Mar 25, 2026

Ingested at

May 23, 2026

Internal sync

Jun 05, 2026

Model version

trialsignal-ai-v1

Normalized confidence

88%

Validation status

validated

Open original registry record
View original source fields

NCT ID

NCT06123754

Title

A Randomized, Controlled, Double-blind, Multicenter Phase III Clinical Study of Envafolimab Plus Platinum-based Doublet Chemotherapy Versus Placebo Plus Platinum-based Doublet Chemotherapy in Patients With Non-small Cell Lung Cancer

Sponsor

3D Medicines (Sichuan) Co., Ltd.

Status

RECRUITING

Phase

PHASE3

Condition raw

Non-small Cell Lung Cancer

Condition normalized

Non-small Cell Lung Cancer

Modality raw

non-small cell lung cancer

Modality normalized

monoclonal antibody

Target raw

Envalfolimab subcutaneously injected+Platinum-based doublet chemotherapy intravenous injection, placebo subcutaneously injected +Platinum-based doublet chemotherapy intravenous injection

Target normalized

Envalfolimab subcutaneously injected+Platinum-based doublet chemotherapy intravenous injection, placebo subcutaneously injected +Platinum-based doublet chemotherapy intravenous injection

Interventions

Envalfolimab subcutaneously injected+Platinum-based doublet chemotherapy intravenous injection, placebo subcutaneously injected +Platinum-based doublet chemotherapy intravenous injection

Public preview

Source record

A Randomized, Controlled, Double-blind, Multicenter Phase III Clinical Study of Envafolimab Plus Platinum-based Doublet Chemotherapy Versus Placebo Plus Platinum-based Doublet Chemotherapy in Patients With Non-small Cell Lung Cancer is a PHASE3 clinical asset sponsored by 3D Medicines (Sichuan) Co., Ltd. in Non-small Cell Lung Cancer. SEO and diligence focus: Envalfolimab subcutaneously injected+Platinum-based doublet chemotherapy intravenous injection, placebo subcutaneously injected +Platinum-based doublet chemotherapy intravenous injection, endpoint relevance, enrollment feasibility, competitive positioning, readout timing and IP durability.

AI-generated analysis supports research triage only. Verify source records, publications, sponsor disclosures and IP databases before making diligence decisions. Model: trialsignal-ai-v1.

Report access

Create an account to unlock this report

Choose the access model that matches the job: one urgent report, reusable credits for project work, or unlimited monthly access with AI and folders.

Full protocol, outcomes, eligibility, contacts and results sections
Patent/IP landscape with verified records when available
Board-ready PDF export with source provenance
Save to folders and synthesize multiple assets in premium workspace
Create account
Sign in

Create a free account first, then unlock a single report, buy credits or subscribe.

TrialSignal

Clinical trial intelligence report

A Randomized, Controlled, Double-blind, Multicenter Phase III Clinical Study of Envafolimab Plus Platinum-based Doublet Chemotherapy Versus Placebo Plus Platinum-based Doublet Chemotherapy in Patients With Non-small Cell Lung Cancer

Source-linked diligence brief with registry provenance, taxonomy normalization and premium analytical context.

Generated

Jun 13, 2026

NCT ID

NCT06123754

Status

RECRUITING

Phase

PHASE3

Sponsor

3D Medicines (Sichuan) Co., Ltd.

Executive brief

Investment-Ready Snapshot

A Randomized, Controlled, Double-blind, Multicenter Phase III Clinical Study of Envafolimab Plus Platinum-based Doublet Chemotherapy Versus Placebo Plus Platinum-based Doublet Chemotherapy in Patients With Non-small Cell Lung Cancer is a PHASE3 clinical asset sponsored by 3D Medicines (Sichuan) Co., Ltd. in Non-small Cell Lung Cancer. SEO and diligence focus: Envalfolimab subcutaneously injected+Platinum-based doublet chemotherapy intravenous injection, placebo subcutaneously injected +Platinum-based doublet chemotherapy intravenous injection, endpoint relevance, enrollment feasibility, competitive positioning, readout timing and IP durability.

Source & freshness

Provenance

SourceClinicalTrials.gov
Source updatedMar 25, 2026
Internal syncJun 05, 2026
Model versiontrialsignal-ai-v1

https://clinicaltrials.gov/study/NCT06123754

Indication

Non-small Cell Lung Cancer

Modality

monoclonal antibody

Target

Envalfolimab subcutaneously injected+Platinum-based doublet chemotherapy intravenous injection, placebo subcutaneously injected +Platinum-based doublet chemotherapy intravenous injection

Intervention

Envalfolimab subcutaneously injected+Platinum-based doublet chemotherapy intravenous injection, placebo subcutaneously injected +Platinum-based doublet chemotherapy intravenous injection

Source record

Protocol Description

Detailed source ingestion pending.

Source record

Outcome Measures

Detailed source ingestion pending.

Source record

Eligibility

Detailed source ingestion pending.

AI analysis

Known Results And Readout Context

Detailed source ingestion pending.

IP intelligence

Patent And IP Landscape

Detailed source ingestion pending.

Source record

Contacts

Detailed source ingestion pending.